Evolent Health Inc. (NYSE:EVH)‘s stock had its “hold” rating restated by investment analysts at Wells Fargo & Co. in a report released on Thursday.

A number of other brokerages also recently issued reports on EVH. Canaccord Genuity set a $31.00 price target on Evolent Health and gave the company a “buy” rating in a report on Tuesday, November 22nd. Zacks Investment Research downgraded Evolent Health from a “buy” rating to a “hold” rating in a report on Monday, November 14th. JPMorgan Chase & Co. initiated coverage on Evolent Health in a report on Friday, October 28th. They issued an “overweight” rating and a $30.00 price target for the company. William Blair reaffirmed an “outperform” rating on shares of Evolent Health in a report on Friday, September 30th. Finally, Leerink Swann reaffirmed a “buy” rating on shares of Evolent Health in a report on Wednesday, October 5th. Two research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $27.83.

Analyst Recommendations for Evolent Health (NYSE:EVH)

Shares of Evolent Health (NYSE:EVH) opened at 18.80 on Thursday. The firm’s market cap is $1.28 billion. Evolent Health has a 52 week low of $8.14 and a 52 week high of $26.84. The stock’s 50 day moving average is $21.03 and its 200-day moving average is $20.98.

Evolent Health (NYSE:EVH) last announced its quarterly earnings results on Wednesday, November 9th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.02. The firm earned $60.20 million during the quarter, compared to the consensus estimate of $58.35 million. Evolent Health had a negative return on equity of 5.54% and a negative net margin of 69.04%. The firm’s quarterly revenue was up 39.0% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share. On average, equities analysts predict that Evolent Health will post ($0.57) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: This article was first posted by Financial Market News and is the sole property of of Financial Market News. If you are accessing this article on another publication, it was copied illegally and reposted in violation of United States & international copyright & trademark laws. The correct version of this article can be read at http://www.financial-market-news.com/evolent-health-inc-evh-earns-hold-rating-from-wells-fargo-co/1212343/.

In other news, President Seth Blackley sold 167,672 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $21.54, for a total transaction of $3,611,654.88. Following the completion of the sale, the president now owns 869,848 shares in the company, valued at $18,736,525.92. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael D’amato purchased 10,000 shares of the business’s stock in a transaction dated Monday, November 14th. The shares were bought at an average price of $17.18 per share, with a total value of $171,800.00. Following the purchase, the director now directly owns 18,183 shares of the company’s stock, valued at $312,383.94. The disclosure for this purchase can be found here. 8.85% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the company. BlackRock Inc. boosted its stake in Evolent Health by 23.8% in the third quarter. BlackRock Inc. now owns 4,506 shares of the company’s stock valued at $111,000 after buying an additional 867 shares during the period. Barclays PLC bought a new stake in Evolent Health during the second quarter valued at approximately $144,000. American International Group Inc. boosted its stake in Evolent Health by 14.9% in the second quarter. American International Group Inc. now owns 8,761 shares of the company’s stock valued at $168,000 after buying an additional 1,134 shares during the period. BlackRock Group LTD boosted its stake in Evolent Health by 201.3% in the third quarter. BlackRock Group LTD now owns 7,270 shares of the company’s stock valued at $178,000 after buying an additional 4,857 shares during the period. Finally, Nationwide Fund Advisors boosted its stake in Evolent Health by 8.5% in the second quarter. Nationwide Fund Advisors now owns 10,109 shares of the company’s stock valued at $194,000 after buying an additional 789 shares during the period. Institutional investors and hedge funds own 51.70% of the company’s stock.

Evolent Health Company Profile

Evolent Health, Inc supports integrated health systems in their migration towards value-based care and population health management. The Company’s services include providing customers with a population management platform, integrated data and analytics capabilities, pharmacy benefit management services and health plan administration services.

5 Day Chart for NYSE:EVH

Receive News & Ratings for Evolent Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.